The expressions of mesothelin in chemosensitive EOC patients with residual tumour size ⩽1 or >1 cm were significantly lower than those in the chemoresistant groups, which indicates that mesothelin can be a potential biomarker to evaluate chemotherapeutic effects on EOC patients. This evidence concerns the gene MSLN and neoplasm.